Skip to main content

SiriusPoint Expands Travel Insurance Platform With World Nomads Acquisition

Tipranks - Fri Feb 13, 4:02PM CST

Valentine's Day Sale - 70% Off

SiriusPoint ( (SPNT) ) just unveiled an announcement.

On February 12, 2026, SiriusPoint’s subsidiary Sirius International UK Holdings II Ltd. agreed to acquire the World Nomads travel insurance business from Australian health insurer nib Group via a share and asset sale. World Nomads, with about $40 million in gross written premium, is a well-established global travel insurance and lifestyle brand that targets independent, lifestyle and adventure travelers, and offers products worldwide.

SiriusPoint announced that its subsidiary International Medical Group will assume World Nomads, a move that will significantly broaden IMG’s travel insurance distribution and extend its footprint into Australia, Brazil and Canada. The acquisition, together with IMG’s recent purchase of global travel assistance provider Assist America, is expected to create a more integrated global insurance and assistance platform, boosting IMG’s presence to 34 countries and enhancing scale and diversification.

Management highlighted that both the World Nomads and Assist America deals are expected to be accretive to return on equity and earnings per share, supporting SiriusPoint’s strategy of building a diversified, high-performing portfolio. The transaction was scheduled to close on the majority of the World Nomads group in the second or third quarter of 2026, with final completion anticipated in the second half of 2027, subject to regulatory approvals and other customary conditions, and is intended to deliver greater reach, enhanced services and long-term value for stakeholders.

The most recent analyst rating on (SPNT) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on SiriusPoint stock, see the SPNT Stock Forecast page.

Spark’s Take on SPNT Stock

According to Spark, TipRanks’ AI Analyst, SPNT is a Outperform.

The score is primarily supported by strong financial performance (notably robust free cash flow growth and conservative leverage) and a positive earnings call featuring strong underwriting metrics and above-target operating ROE. These strengths are moderated by mixed technical momentum signals and a valuation that is reasonable but not clearly compelling, with no dividend yield data provided.

To see Spark’s full report on SPNT stock, click here.

More about SiriusPoint

SiriusPoint Ltd. is a Bermuda-headquartered global underwriter of insurance and reinsurance, listed on the NYSE under ticker SPNT, with licenses to write Property & Casualty and Accident & Health business worldwide. The company operates through offices in New York, London, Stockholm and other locations, and leverages strategic partnerships with Managing General Agents and Program Administrators to strengthen distribution capabilities.

With approximately $2.8 billion in total capital, SiriusPoint’s operating companies hold financial strength ratings of A- (Excellent) from AM Best, S&P and Fitch, and A3 from Moody’s, underscoring solid capitalization and credit quality. Its subsidiary International Medical Group, founded in 1990, provides global insurance benefits and assistance services, including travel and international medical insurance, and supports travelers, workers and students abroad.

World Nomads, founded in 2002, is a global travel insurance and lifestyle brand focused on adventurous and independent travelers, offering coverage for emergency medical and evacuation costs, trip cancellation, delays, baggage and more than 250 adventure sports and activities. It serves travelers from over 100 countries and integrates a charitable Footprints program that channels customer donations into community development projects worldwide.

Average Trading Volume: 654,966

Technical Sentiment Signal: Buy

Current Market Cap: $2.34B

Learn more about SPNT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.